Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the feasibility of a randomized, double blind, placebo controlled trial of add-on rituximab for non-splenectomized adults with acute immune thrombocytopenic purpura (ITP).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

NCT04323748

Immune Thrombocytopenic Purpura

UNKNOWN PHASE1

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT01713738

Idiopathic Thrombocytopenic Purpura (ITP) Immune Thrombocytopenic Purpura (ITP)

COMPLETED PHASE1/PHASE2

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

NCT05338190

Primary Immune Thrombocytopenia (ITP)

RECRUITING PHASE3

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

NCT01101295

Purpura, Thrombocytopenic, Idiopathic Autoimmune Thrombocytopenia

UNKNOWN

Rituximab as Second Line Treatment for ITP

NCT00344149

Immune Thrombocytopenia (ITP)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by severe thrombocytopenia and bleeding. With current standard therapies, adult-onset ITP tends to recur thus exposing patients to prolonged risks of hemorrhage and toxicities of standard treatments. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effectively raise the platelet count in some patients with ITP and there is clinical and biological evidence to suggest that, if given early, rituximab may prevent ITP relapses.

We have designed a randomized, double blind, placebo controlled pilot trial of rituximab for the treatment of non-splenectomized adults with acute ITP who are receiving standard treatments. The primary objectives of this trial are to determine the feasibility of recruitment, randomization and blinding; the safety of rituximab in ITP; and the event rate in the control group which will be used to calculate the sample size for a larger trial. Secondary objectives are to determine rates of 6-month event free survival where an event is defined as any of: a platelet count \<50; the need for rescue treatment; or significant bleeding. Data from this pilot trial will inform the design of a larger phase III trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Purpura, Thrombocytopenic, Idiopathic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Rituximab

Group Type ACTIVE_COMPARATOR

Rituximab

Intervention Type DRUG

375mg/m2 per week for 4 consecutive weeks

B

Saline placebo iv infusion

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Saline IV placebo once per week for 4 consecutive weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

375mg/m2 per week for 4 consecutive weeks

Intervention Type DRUG

Placebo

Saline IV placebo once per week for 4 consecutive weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rituxan, Mabthera

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-splenectomized patients with acute ITP, where "acute ITP" is defined as a platelet count below 30 at the time that standard treatment was recommended by a physician and for which no treatment had been received for the preceding 30 days.
* Must be receiving standard ITP treatment.

Exclusion Criteria

* Cardiac arrhythmia.
* Uncontrolled hypertension or inability to hold antihypertensive medications for 12 hours prior to and throughout study drug infusions.
* Known coronary artery disease, angina pectoris or myocardial infarction within the last year.
* Significant pulmonary disease within the last year.
* Stroke, transient ischemic attack or venous thrombosis within the last year.
* Secondary causes of thrombocytopenia (splenomegaly \[palpable spleen or radiologically confirmed \>14 cm\], drug-induced thrombocytopenia, hereditary thrombocytopenia, microangiopathic hemolytic anemia, myelodysplastic syndrome).
* Chronic lymphocytic leukemia or lymphoma.
* Active or metastatic cancer.
* History of hepatitis B or C or HIV.
* Active infection in the 4 weeks before randomization.
* Inherited coagulation factor deficiency.
* Aspirin, aspirin-containing compounds, salicylates, non-steroidal anti-inflammatory medications (NSAIDS) medications, clopidogrel or ticlopidine in the 7 days preceding study drug infusions; vitamin K antagonists (warfarin) in the 3 days preceding study drug infusions; unfractionated heparin or low molecular weight heparin in the 24 hours preceding study drug infusions.
* Elevated INR or prolonged PTT; LDH, serum creatinine, liver function tests (AST/SGOT, ALT/SGPT, alkaline phosphatase, total bilirubin) increased more than 1.5 times upper limit of normal.
* Prior rituximab treatment.
* Unable to schedule 4 weekly study infusions.
* Pregnancy or breastfeeding.
* Known sensitivity to murine proteins, Chinese Hamster Ovary (CHO) cell proteins or to any component of rituximab.
* Participation in another clinical trial.
* Geographic inaccessibility.
* Failure to provide written informed consent.
* Any additional laboratory test result, health related illness or other diagnosis which, in the opinion of the treating physician, may put the subject's health or safety at risk.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No